Kaposi's Sarcoma Associated Herpes Virus (KSHV) Induced COX-2: A Key Factor in Latency, Inflammation, Angiogenesis, Cell Survival and Invasion
Kaposi's sarcoma (KS), an enigmatic endothelial cell vascular neoplasm, is characterized by the proliferation of spindle shaped endothelial cells, inflammatory cytokines (ICs), growth factors (GFs) and angiogenic factors. KSHV is etiologically linked to KS and expresses its latent genes in KS lesion endothelial cells. Primary infection of human micro vascular endothelial cells (HMVEC-d) results in the establishment of latent infection and reprogramming of host genes, and cyclooxygenase-2 (COX-2) is one of the highly up-regulated genes. Our previous study suggested a role for COX-2 in the establishment and maintenance of KSHV latency. Here, we examined the role of COX-2 in the induction of ICs, GFs, angiogenesis and invasive events occurring during KSHV de novo infection of endothelial cells. A significant amount of COX-2 was detected in KS tissue sections. Telomerase-immortalized human umbilical vein endothelial cells supporting KSHV stable latency (TIVE-LTC) expressed elevated levels of functional COX-2 and microsomal PGE2 synthase (m-PGES), and secreted the predominant eicosanoid inflammatory metabolite PGE2. Infected HMVEC-d and TIVE-LTC cells secreted a variety of ICs, GFs, angiogenic factors and matrix metalloproteinases (MMPs), which were significantly abrogated by COX-2 inhibition either by chemical inhibitors or by siRNA. The ability of these factors to induce tube formation of uninfected endothelial cells was also inhibited. PGE2, secreted early during KSHV infection, profoundly increased the adhesion of uninfected endothelial cells to fibronectin by activating the small G protein Rac1. COX-2 inhibition considerably reduced KSHV latent ORF73 gene expression and survival of TIVE-LTC cells. Collectively, these studies underscore the pivotal role of KSHV induced COX-2/PGE2 in creating KS lesion like microenvironment during de novo infection. Since COX-2 plays multiple roles in KSHV latent gene expression, which themselves are powerful mediators of cytokine induction, anti-apoptosis, cell survival and viral genome maintainence, effective inhibition of COX-2 via well-characterized clinically approved COX-2 inhibitors could potentially be used in treatment to control latent KSHV infection and ameliorate KS.
Vyšlo v časopise:
Kaposi's Sarcoma Associated Herpes Virus (KSHV) Induced COX-2: A Key Factor in Latency, Inflammation, Angiogenesis, Cell Survival and Invasion. PLoS Pathog 6(2): e32767. doi:10.1371/journal.ppat.1000777
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.ppat.1000777
Souhrn
Kaposi's sarcoma (KS), an enigmatic endothelial cell vascular neoplasm, is characterized by the proliferation of spindle shaped endothelial cells, inflammatory cytokines (ICs), growth factors (GFs) and angiogenic factors. KSHV is etiologically linked to KS and expresses its latent genes in KS lesion endothelial cells. Primary infection of human micro vascular endothelial cells (HMVEC-d) results in the establishment of latent infection and reprogramming of host genes, and cyclooxygenase-2 (COX-2) is one of the highly up-regulated genes. Our previous study suggested a role for COX-2 in the establishment and maintenance of KSHV latency. Here, we examined the role of COX-2 in the induction of ICs, GFs, angiogenesis and invasive events occurring during KSHV de novo infection of endothelial cells. A significant amount of COX-2 was detected in KS tissue sections. Telomerase-immortalized human umbilical vein endothelial cells supporting KSHV stable latency (TIVE-LTC) expressed elevated levels of functional COX-2 and microsomal PGE2 synthase (m-PGES), and secreted the predominant eicosanoid inflammatory metabolite PGE2. Infected HMVEC-d and TIVE-LTC cells secreted a variety of ICs, GFs, angiogenic factors and matrix metalloproteinases (MMPs), which were significantly abrogated by COX-2 inhibition either by chemical inhibitors or by siRNA. The ability of these factors to induce tube formation of uninfected endothelial cells was also inhibited. PGE2, secreted early during KSHV infection, profoundly increased the adhesion of uninfected endothelial cells to fibronectin by activating the small G protein Rac1. COX-2 inhibition considerably reduced KSHV latent ORF73 gene expression and survival of TIVE-LTC cells. Collectively, these studies underscore the pivotal role of KSHV induced COX-2/PGE2 in creating KS lesion like microenvironment during de novo infection. Since COX-2 plays multiple roles in KSHV latent gene expression, which themselves are powerful mediators of cytokine induction, anti-apoptosis, cell survival and viral genome maintainence, effective inhibition of COX-2 via well-characterized clinically approved COX-2 inhibitors could potentially be used in treatment to control latent KSHV infection and ameliorate KS.
Zdroje
1. BoshoffC
WeissRA
1998 Kaposi's sarcoma-associated herpesvirus. Adv Cancer Res 75 57 86
2. DupinN
FisherC
KellamP
AriadS
TulliezM
1999 Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A 96 4546 4551
3. FidlerIJ
SinghRK
YonedaJ
KumarR
XuL
2000 Critical determinants of neoplastic angiogenesis. Cancer J 6 Suppl 3 S225 236
4. CarmelietP
JainRK
2000 Angiogenesis in cancer and other diseases. Nature 407 249 257
5. VartRJ
NikitenkoLL
LagosD
TrotterMW
CannonM
2007 Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6 and G-protein-coupled receptor regulate angiopoietin-2 expression in lymphatic endothelial cells. Cancer Res 67 4042 4051
6. SadagopanS
Sharma-WaliaN
VeettilMV
BotteroV
LevineR
2009 Kaposi's sarcoma-associated herpesvirus upregulates angiogenin during infection of human dermal microvascular endothelial cells, which induces 45S rRNA synthesis, antiapoptosis, cell proliferation, migration, and angiogenesis. J Virol 83 3342 3364
7. McAllisterSC
HansenSG
RuhlRA
RaggoCM
DeFilippisVR
2004 Kaposi sarcoma-associated herpesvirus (KSHV) induces heme oxygenase-1 expression and activity in KSHV-infected endothelial cells. Blood 103 3465 3473
8. Di BartoloDL
CannonM
LiuYF
RenneR
ChadburnA
2008 KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor. Blood 111 4731 4740
9. BoshoffC
WeissRA
1997 Aetiology of Kaposi's sarcoma: current understanding and implications for therapy. Mol Med Today 3 488 494
10. BlackbournDJ
LennetteE
KlenckeB
MosesA
ChandranB
2000 The restricted cellular host range of human herpesvirus 8. Aids 14 1123 1133
11. HaywardGS
2003 Initiation of angiogenic Kaposi's sarcoma lesions. Cancer Cell 3 1 3
12. QianLW
XieJ
YeF
GaoSJ
2007 Kaposi's sarcoma-associated herpesvirus infection promotes invasion of primary human umbilical vein endothelial cells by inducing matrix metalloproteinases. J Virol 81 7001 7010
13. RussoJJ
BohenzkyRA
ChienMC
ChenJ
YanM
1996 Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci U S A 93 14862 14867
14. NeipelF
AlbrechtJC
EnsserA
HuangYQ
LiJJ
1997 Human herpesvirus 8 encodes a homolog of interleukin-6. J Virol 71 839 842
15. BaisC
Van GeelenA
ErolesP
MutluA
ChiozziniC
2003 Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/ KDR. Cancer Cell 3 131 143
16. AttigaFA
FernandezPM
WeeraratnaAT
ManyakMJ
PatiernoSR
2000 Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 60 4629 4637
17. MoorePS
ChangY
2001 Molecular virology of Kaposi's sarcoma-associated herpesvirus. Philos Trans R Soc Lond B Biol Sci 356 499 516
18. McCormickC
GanemD
2005 The kaposin B protein of KSHV activates the p38/MK2 pathway and stabilizes cytokine mRNAs. Science 307 739 741
19. MurphyPM
1997 Pirated genes in Kaposi's sarcoma. Nature 385 296 297, 299
20. MilliganS
RobinsonM
O'DonnellE
BlackbournDJ
2004 Inflammatory cytokines inhibit Kaposi's sarcoma-associated herpesvirus lytic gene transcription in in vitro-infected endothelial cells. J Virol 78 2591 2596
21. BoshoffC
GaoSJ
HealyLE
MatthewsS
ThomasAJ
1998 Establishing a KSHV+ cell line (BCP-1) from peripheral blood and characterizing its growth in Nod/SCID mice. Blood 91 1671 1679
22. StaskusKA
ZhongW
GebhardK
HerndierB
WangH
1997 Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol 71 715 719
23. DittmerD
LagunoffM
RenneR
StaskusK
HaaseA
1998 A cluster of latently expressed genes in Kaposi's sarcoma-associated herpesvirus. J Virol 72 8309 8315
24. McClureLV
SullivanCS
2008 Kaposi's sarcoma herpes virus taps into a host microRNA regulatory network. Cell Host Microbe 3 1 3
25. NaranattPP
KrishnanHH
SvojanovskySR
BloomerC
MathurS
2004 Host gene induction and transcriptional reprogramming in Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8)-infected endothelial, fibroblast, and B cells: insights into modulation events early during infection. Cancer Res 64 72 84
26. Sharma-WaliaN
RaghuH
SadagopanS
SivakumarR
VeettilMV
2006 Cyclooxygenase 2 induced by Kaposi's sarcoma-associated herpesvirus early during in vitro infection of target cells plays a role in the maintenance of latent viral gene expression. J Virol 80 6534 6552
27. ShelbyBD
LaMarcaHL
McFerrinHE
NelsonAB
LaskyJA
2007 Kaposi's sarcoma associated herpesvirus G-protein coupled receptor activation of cyclooxygenase-2 in vascular endothelial cells. Virol J 4 87
28. BrinkmannMM
PietrekM
Dittrich-BreiholzO
KrachtM
SchulzTF
2007 Modulation of host gene expression by the K15 protein of Kaposi's sarcoma-associated herpesvirus. J Virol 81 42 58
29. VaneJR
BottingRM
1998 Anti-inflammatory drugs and their mechanism of action. Inflamm Res 47 Suppl 2 S78 87
30. SmithWL
DeWittDL
GaravitoRM
2000 Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69 145 182
31. LinDT
SubbaramaiahK
ShahJP
DannenbergAJ
BoyleJO
2002 Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck 24 792 799
32. DannenbergAJ
SubbaramaiahK
2003 Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 4 431 436
33. DempkeW
RieC
GrotheyA
SchmollHJ
2001 Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol 127 411 417
34. Sharma-WaliaN
KrishnanHH
NaranattPP
ZengL
SmithMS
2005 ERK1/2 and MEK1/2 induced by Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) early during infection of target cells are essential for expression of viral genes and for establishment of infection. J Virol 79 10308 10329
35. Sharma-WaliaN
NaranattPP
KrishnanHH
ZengL
ChandranB
2004 Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 envelope glycoprotein gB induces the integrin-dependent focal adhesion kinase-Src-phosphatidylinositol 3-kinase-rho GTPase signal pathways and cytoskeletal rearrangements. J Virol 78 4207 4223
36. TiscorniaG
SingerO
VermaIM
2006 Design and cloning of lentiviral vectors expressing small interfering RNAs. Nat Protoc 1 234 240
37. SivakumarR
Sharma-WaliaN
RaghuH
VeettilMV
SadagopanS
2008 Kaposi's sarcoma-associated herpesvirus induces sustained levels of vascular endothelial growth factors A and C early during in vitro infection of human microvascular dermal endothelial cells: biological implications. J Virol 82 1759 1776
38. CesarmanE
ChangY
MoorePS
SaidJW
KnowlesDM
1995 Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 332 1186 1191
39. GanemD
2006 KSHV infection and the pathogenesis of Kaposi's sarcoma. Annu Rev Pathol 1 273 296
40. CornelissenM
van der KuylAC
van den BurgR
ZorgdragerF
van NoeselCJ
2003 Gene expression profile of AIDS-related Kaposi's sarcoma. BMC Cancer 3 7
41. KrishnanHH
NaranattPP
SmithMS
ZengL
BloomerC
2004 Concurrent expression of latent and a limited number of lytic genes with immune modulation and antiapoptotic function by Kaposi's sarcoma-associated herpesvirus early during infection of primary endothelial and fibroblast cells and subsequent decline of lytic gene expression. J Virol 78 3601 3620
42. AnFQ
FolarinHM
CompitelloN
RothJ
GersonSL
2006 Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo. J Virol 80 4833 4846
43. JiangXH
LamSK
LinMC
JiangSH
KungHF
2002 Novel target for induction of apoptosis by cyclo-oxygenase-2 inhibitor SC-236 through a protein kinase C-beta(1)-dependent pathway. Oncogene 21 6113 6122
44. HeQ
LuoX
JinW
HuangY
ReddyMV
2008 Celecoxib and a novel COX-2 inhibitor ON09310 upregulate death receptor 5 expression via GADD153/CHOP. Oncogene 27 2656 2660
45. von RahdenBH
SteinHJ
PuhringerF
KochI
LangerR
2005 Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma. Cancer Res 65 5038 5044
46. VisseR
NagaseH
2003 Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92 827 839
47. OverallCM
KleifeldO
2006 Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer 94 941 946
48. KleinG
VellengaE
FraaijeMW
KampsWA
de BontES
2004 The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol 50 87 100
49. PantanowitzL
DezubeBJ
Hernandez-BarrantesS
TahanSR
DabbousMK
2006 Matrix metalloproteinases in the progression and regression of Kaposi's sarcoma. J Cutan Pathol 33 793 798
50. RidleyAJ
2001 Rho GTPases and cell migration. J Cell Sci 114 2713 2722
51. BurridgeK
WennerbergK
2004 Rho and Rac take center stage. Cell 116 167 179
52. VeettilMV
Sharma-WaliaN
SadagopanS
RaghuH
SivakumarR
2006 RhoA-GTPase facilitates entry of Kaposi's sarcoma-associated herpesvirus into adherent target cells in a Src-dependent manner. J Virol 80 11432 11446
53. DormondO
BezziM
MariottiA
RueggC
2002 Prostaglandin E2 promotes integrin alpha Vbeta 3-dependent endothelial cell adhesion, rac-activation, and spreading through cAMP/PKA-dependent signaling. J Biol Chem 277 45838 45846
54. ErkanliS
BolatF
KayaselcukF
DemirhanB
KuscuE
2007 COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma. Gynecol Oncol 104 320 325
55. BaopingY
GuoyongH
JiepingY
ZongxueR
HeshengL
2004 Cyclooxygenase-2 inhibitor nimesulide suppresses telomerase activity by blocking Akt/PKB activation in gastric cancer cell line. Dig Dis Sci 49 948 953
56. SadagopanS
Sharma-WaliaN
VeettilMV
RaghuH
SivakumarR
2007 Kaposi's sarcoma-associated herpesvirus induces sustained NF-kappaB activation during de novo infection of primary human dermal microvascular endothelial cells that is essential for viral gene expression. J Virol 81 3949 3968
57. AmbrusJL
StollHL
KleinEA
KarakousisCP
StadlerS
1992 Increased prostaglandin E2 and cAMP phosphodiesterase levels in Kaposi's sarcoma–a virus against host defense mechanism. Res Commun Chem Pathol Pharmacol 78 249 252
58. RossielloL
RuoccoE
SignorielloG
MicheliP
RienzoM
2007 Evidence of COX-1 and COX-2 expression in Kaposi's sarcoma tissues. Eur J Cancer 43 1232 1241
59. GalloO
FranchiA
MagnelliL
SardiI
VannacciA
2001 Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 3 53 61
60. HongYK
ForemanK
ShinJW
HirakawaS
CurryCL
2004 Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat Genet 36 683 685
61. GrogerM
LoeweR
HolnthonerW
EmbacherR
PillingerM
2004 IL-3 induces expression of lymphatic markers Prox-1 and podoplanin in human endothelial cells. J Immunol 173 7161 7169
62. InoueH
TakamoriM
ShimoyamaY
IshibashiH
YamamotoS
2002 Regulation by PGE2 of the production of interleukin-6, macrophage colony stimulating factor, and vascular endothelial growth factor in human synovial fibroblasts. Br J Pharmacol 136 287 295
63. WangD
MannJR
DuBoisRN
2005 The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology 128 1445 1461
64. LeeDC
ChuaDT
WeiWI
ShamJS
LauAS
2007 Induction of matrix metalloproteinases by Epstein-Barr virus latent membrane protein 1 isolated from nasopharyngeal carcinoma. Biomed Pharmacother 61 520 526
65. TakeshitaH
YoshizakiT
MillerWE
SatoH
FurukawaM
1999 Matrix metalloproteinase 9 expression is induced by Epstein-Barr virus latent membrane protein 1 C-terminal activation regions 1 and 2. J Virol 73 5548 5555
66. LuJ
ChuaHH
ChenSY
ChenJY
TsaiCH
2003 Regulation of matrix metalloproteinase-1 by Epstein-Barr virus proteins. Cancer Res 63 256 262
67. ChungTW
MoonSK
LeeYC
KimJG
KoJH
2002 Enhanced expression of matrix metalloproteinase-9 by hepatitis B virus infection in liver cells. Arch Biochem Biophys 408 147 154
68. MastroianniCM
LiuzziGM
2007 Matrix metalloproteinase dysregulation in HIV infection: implications for therapeutic strategies. Trends Mol Med 13 449 459
69. CaoR
ErikssonA
KuboH
AlitaloK
CaoY
2004 Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circ Res 94 664 670
70. KoskivirtaI
RahkonenO
MayranpaaM
PakkanenS
HusheemM
2006 Tissue inhibitor of metalloproteinases 4 (TIMP4) is involved in inflammatory processes of human cardiovascular pathology. Histochem Cell Biol 126 335 342
71. ChircoR
LiuXW
JungKK
KimHR
2006 Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 25 99 113
72. YaoL
SalvucciO
CardonesAR
HwangST
AokiY
2003 Selective expression of stromal-derived factor-1 in the capillary vascular endothelium plays a role in Kaposi sarcoma pathogenesis. Blood 102 3900 3905
73. FujimuroM
WuFY
ApRhysC
KajumbulaH
YoungDB
2003 A novel viral mechanism for dysregulation of beta-catenin in Kaposi's sarcoma-associated herpesvirus latency. Nat Med 9 300 306
74. OttingerM
ChristallaT
NathanK
BrinkmannMM
Viejo-BorbollaA
2006 Kaposi's sarcoma-associated herpesvirus LANA-1 interacts with the short variant of BRD4 and releases cells from a BRD4- and BRD2/RING3-induced G1 cell cycle arrest. J Virol 80 10772 10786
75. LimK
HanC
XuL
IsseK
DemetrisAJ
2008 Cyclooxygenase-2-derived prostaglandin E2 activates beta-catenin in human cholangiocarcinoma cells: evidence for inhibition of these signaling pathways by omega 3 polyunsaturated fatty acids. Cancer Res 68 553 560
76. SawasdikosolS
PyarajanS
AlzabinS
MatejovicG
BurakoffSJ
2007 Prostaglandin E2 activates HPK1 kinase activity via a PKA-dependent pathway. J Biol Chem 282 34693 34699
77. PhamL
BezouglaiaO
CamargoPM
NervinaJM
TetradisS
2007 Prostanoids induce egr1 gene expression in cementoblastic OCCM cells. J Periodontal Res 42 486 493
78. FriasMA
RebsamenMC
Gerber-WichtC
LangU
2007 Prostaglandin E2 activates Stat3 in neonatal rat ventricular cardiomyocytes: A role in cardiac hypertrophy. Cardiovasc Res 73 57 65
79. BuchananFG
DuBoisRN
2006 Connecting COX-2 and Wnt in cancer. Cancer Cell 9 6 8
80. KrysanK
ReckampKL
DalwadiH
SharmaS
RozengurtE
2005 Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res 65 6275 6281
81. YamakiT
EndohK
MiyaharaM
NagamineI
Thi Thu HuongN
2004 Prostaglandin E2 activates Src signaling in lung adenocarcinoma cell via EP3. Cancer Lett 214 115 120
82. Mochizuki-OdaN
MoriK
NegishiM
ItoS
1991 Prostaglandin E2 activates Ca2+ channels in bovine adrenal chromaffin cells. J Neurochem 56 541 547
83. MicaliA
MediciN
SottileA
VenzaM
VenzaI
1996 Prostaglandin E2 induction of binding activity to CRE and AP-2 elements in human T lymphocytes. Cell Immunol 174 99 105
84. LiuXH
KirschenbaumA
LuM
YaoS
DosoretzA
2002 Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line. J Biol Chem 277 50081 50086
85. WangX
KleinRD
2007 Prostaglandin E2 induces vascular endothelial growth factor secretion in prostate cancer cells through EP2 receptor-mediated cAMP pathway. Mol Carcinog 46 912 923
86. ItoH
DuxburyM
BenoitE
ClancyTE
ZinnerMJ
2004 Prostaglandin E2 enhances pancreatic cancer invasiveness through an Ets-1-dependent induction of matrix metalloproteinase-2. Cancer Res 64 7439 7446
87. BradburyD
ClarkeD
SeedhouseC
CorbettL
StocksJ
2005 Vascular endothelial growth factor induction by prostaglandin E2 in human airway smooth muscle cells is mediated by E prostanoid EP2/EP4 receptors and SP-1 transcription factor binding sites. J Biol Chem 280 29993 30000
88. ChuangPC
SunHS
ChenTM
TsaiSJ
2006 Prostaglandin E2 induces fibroblast growth factor 9 via EP3-dependent protein kinase Cdelta and Elk-1 signaling. Mol Cell Biol 26 8281 8292
89. GeorgeRJ
SturmoskiMA
AnantS
HouchenCW
2007 EP4 mediates PGE2 dependent cell survival through the PI3 kinase/AKT pathway. Prostaglandins Other Lipid Mediat 83 112 120
90. YeFC
ZhouFC
XieJP
KangT
GreeneW
2008 Kaposi's sarcoma-associated herpesvirus latent gene vFLIP inhibits viral lytic replication through NF-kappaB-mediated suppression of the AP-1 pathway: a novel mechanism of virus control of latency. J Virol 82 4235 4249
91. CaiQ
LanK
VermaSC
SiH
LinD
2006 Kaposi's sarcoma-associated herpesvirus latent protein LANA interacts with HIF-1 alpha to upregulate RTA expression during hypoxia: Latency control under low oxygen conditions. J Virol 80 7965 7975
92. LanK
KuppersDA
RobertsonES
2005 Kaposi's sarcoma-associated herpesvirus reactivation is regulated by interaction of latency-associated nuclear antigen with recombination signal sequence-binding protein Jkappa, the major downstream effector of the Notch signaling pathway. J Virol 79 3468 3478
93. DeWittDL
1999 Cox-2-selective inhibitors: the new super aspirins. Mol Pharmacol 55 625 631
94. SunQ
LiuQ
ZhengY
CaoX
2008 Rapamycin suppresses TLR4-triggered IL-6 and PGE(2) production of colon cancer cells by inhibiting TLR4 expression and NF-kappaB activation. Mol Immunol 45 2929 2936
95. ManningDS
SheehanKM
ByrneMF
KayEW
MurrayFE
2007 Cyclooxygenase-2 expression in chronic hepatitis C and the effect of interferon alpha treatment. J Gastroenterol Hepatol 22 1633 1637
96. DuffM
StapletonPP
MestreJR
MaddaliS
SmythGP
2003 Cyclooxygenase-2 inhibition improves macrophage function in melanoma and increases the antineoplastic activity of interferon gamma. Ann Surg Oncol 10 305 313
97. NakanishiY
KamijoR
TakizawaK
HatoriM
NagumoM
2001 Inhibitors of cyclooxygenase-2 (COX-2) suppressed the proliferation and differentiation of human leukaemia cell lines. Eur J Cancer 37 1570 1578
Štítky
Hygiena a epidemiológia Infekčné lekárstvo LaboratóriumČlánok vyšiel v časopise
PLOS Pathogens
2010 Číslo 2
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- Koronavirus hýbe světem: Víte jak se chránit a jak postupovat v případě podezření?
Najčítanejšie v tomto čísle
- Caspase-1 Activation via Rho GTPases: A Common Theme in Mucosal Infections?
- Kaposi's Sarcoma Associated Herpes Virus (KSHV) Induced COX-2: A Key Factor in Latency, Inflammation, Angiogenesis, Cell Survival and Invasion
- IL-1β Processing in Host Defense: Beyond the Inflammasomes
- Reverse Genetics in Predicts ARF Cycling Is Essential for Drug Resistance and Virulence